Assessing platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: An analysis across TKI generations.

Ryan Cooper, Dhruv Ramaswami, Jacob Thomas, Jorge J. Nieva, Robert HsuResearch Square 2024 · DOI

Abstract

The prognostic value of the platelet-lymphocyte ratio (PLR) was found to be more significant in patients treated with 1st or 2nd generation tyrosine kinase inhibitors (TKIs) compared to those treated with the 3rd generation TKI, osimertinib. These findings suggest that 3rd generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously associated with poor survival. Significant changes in peripheral cell counts further indicate that tumor microenvironment modulation varies depending on the generation of TKI received.

Introduction

In the management of Non-Small Cell Lung Cancer (NSCLC), the advent of Tyrosine Kinase Inhibitors (TKIs) has revolutionized treatment for patients with EGFR mutations. However, clinical response remains heterogeneous. Researchers are increasingly focused on identifying inexpensive, blood-based biomarkers—such as the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR)—to predict progression-free survival (PFS).

Systemic inflammation is a known negative prognostic factor in cancer. While a high PLR has historically correlated with shorter survival in patients receiving 1st- and 2nd-generation TKIs (e.g., erlotinib, afatinib), its relevance in the era of more potent 3rd-generation inhibitors like osimertinib was previously unclear. This study investigates whether osimertinib can mitigate the negative prognostic impact of high baseline inflammation.

Methods and Datasets

This retrospective cohort study analyzed 151 patients treated at the University of Southern California (USC) medical centers between 2015 and 2023. The initial pool consisted of 607 NSCLC patients from the Norris Comprehensive Cancer Center, Keck Hospital of USC, and Los Angeles General Medical Center. Inclusion criteria required confirmed EGFR mutations and treatment with an EGFR TKI.

Table 1: Patient Demographics and Clinical Characteristics at Diagnosis

Patients were stratified into two cohorts: those receiving 1st/2nd generation TKIs and those receiving 3rd generation TKIs. A PLR threshold of 180 was established to categorize patients into "high" ($\ge 180$) or "low" ($< 180$) inflammatory states. The study also included a longitudinal analysis of absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and platelets at various intervals (6 weeks to 12 months).

Key Results

The study revealed a stark difference in the prognostic value of PLR between TKI generations.

  • 1st/2nd Generation TKIs: Patients with a low PLR ($< 180$) achieved a median PFS of 16.6 months, compared to only 10.5 months for those with a high PLR ($p = 0.0163$).
  • 3rd Generation (Osimertinib): The prognostic gap closed significantly. Patients with low PLR had a PFS of 15.7 months versus 11.7 months for high PLR patients, a difference that was not statistically significant ($p = 0.4932$).
Table 2: Clinical Parameters at TKI Initiation, including Inflammatory Markers

Furthermore, patients on osimertinib experienced a more pronounced decrease in ALC at 6 weeks and a significant reduction in platelets at 6 weeks and 3 months compared to the earlier TKI group. Multivariate analysis indicated that while PLR is a valuable signal, it is most effective when considered alongside other clinical variables like BMI and performance status rather than as an independent predictor.

Discussion and Future Directions

The findings suggest that osimertinib acts as an "equalizer," maintaining efficacy regardless of a patient's baseline inflammatory state. This may be due to the drug's more aggressive modulation of the systemic inflammatory environment, as evidenced by the rapid decline in lymphocyte and platelet counts.

However, the study is limited by its retrospective nature and the relatively small sample size in certain subgroups. Additionally, temporal bias exists because osimertinib was approved more recently than its predecessors. Future prospective trials are necessary to determine if combining PLR with other clinical markers can refine prognostic tools for clinicians as targeted therapy continues to evolve.

Summary updated

Abstract

The prognostic value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation <i>EGFR</i> TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variability tumor microenvironment changes dependent on the generation of TKI received.
BibTeX
@inproceedings{cooper2024assessing,
  author = {Ryan Cooper and Dhruv Ramaswami and Jacob Thomas and Jorge J. Nieva and Robert Hsu},
  title = {{Assessing platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: An analysis across TKI generations.}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4930668/v1},
}
Figure